Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 118

Sort by

Sort Order Select

Journal Articles

Liquid biopsy for non-invasive molecular characterization and measurable residual disease analysis in multiple myeloma

Blood (2025) 146 (Supplement 1): 2208.

https://doi.org/10.1182/blood-2025-2208

Published: 2025

Journal Articles

Impact of IKZFplus status and ABL1 kinase domain mutations in patients with newly diagnosed Philadelphia-chromosome positive acute lymphoblastic leukemia receiving imatinib and chemotherapy followed by allogeneic SCT within GMALL07/03

Blood (2025) 146 (Supplement 1): 3373.

https://doi.org/10.1182/blood-2025-3373

Published: 2025

Journal Articles

First promising results in younger adult patients (<65 yrs) with newly diagnosed ph/BCR::ABL positive ALL treated within the randomized GMALL evolve trial

Fabian Lang, Heike Pfeifer, Boris Böll, Knut Wendelin, Andreas Viardot, Andreas Burchert, Georg-Nikolaus Franke, Sonja Martin, Stefan Schwartz, Joerg Westermann, Klaus Wethmar, Monika Brüggemann, Lena Reiser, Thomas Oellerich, Hubert Serve, Nicola Gökbuget

Blood (2025) 146 (Supplement 1): 3342.

https://doi.org/10.1182/blood-2025-3342

Published: 2025

Journal Articles

IL-1β-induced signaling modulates cytokine release and apoptosis in IDH1-mutant AML

Blood (2025) 146 (Supplement 1): 772.

https://doi.org/10.1182/blood-2025-772

Published: 2025

Journal Articles

Late re-expansion and high-level persistence of CAR T-cells can be driven by single CAR+ T-cell clones without clinically evident CAR+ T-cell lymphoma

Fabian Müller, Nora Rebecca Schwingen, Anne Hartebrodt, Nicolai Meyerhoefer, Guranda Chitadze, Soraya Kharboutli, Heiko Bruns, Arif Ekici, Kerstin Schäfer-Eckart, Stefan Knop, Frederik Graw, David Blumenthal, Michael Rehli, Monika Brüggemann, Andreas Mackensen, Simon Voelkl

Blood (2025) 146 (Supplement 1): 4171.

https://doi.org/10.1182/blood-2025-4171

Published: 2025

Journal Articles

Outcome of adult B-precursor acute lymphoblastic leukemia (ALL) treated with blinatumomab in addition to chemotherapy independent of MRD: First results from the national GMALL registry

Blood (2025) 146 (Supplement 1): 5124.

https://doi.org/10.1182/blood-2025-5124

Published: 2025

Journal Articles

Efficacy of single-agent subcutaneous blinatumomab in adults with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL): Results from a phase 1/2 dose expansion study with extended follow-up

Blood (2025) 146 (Supplement 1): 5117.

https://doi.org/10.1182/blood-2025-5117

Published: 2025

Journal Articles

Baseline T-cell fitness and subtype-specific CD19 loss as drivers of blinatumomab resistance in B-ALL

Sonja Bendig, Miriam Kelm, Anna Laqua, Monika Szczepanowski, Thomas Beder, Nadine Wolgast, Mayukh Mondal, Malwine Barz, Alina Hartmann, Lars Fransecky, Jessica Stoldt, Nicola Gökbuget, Lorenz Bastian, Claudia Baldus, Monika Brüggemann, Guranda Chitadze

Blood (2025) 146 (Supplement 1): 32.

https://doi.org/10.1182/blood-2025-32

Published: 2025

Journal Articles

NGS-based IG/TR gene rearrangement profiling in acute lymphoblastic leukemia: age dependence of immunogenetic maturation

Blood (2025) 146 (5): 585–589.

https://doi.org/10.1182/blood.2024027175

Published: 2025

Includes: Supplemental data

Journal Articles

MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trial

Blood (2025) 145 (12): 1282–1292.

https://doi.org/10.1182/blood.2024026685

Published: 2025

Includes: Supplemental data

Journal Articles

Preclinical Development of a Novel Humanized and Fc-Engineered Antibody-Drug Conjugate for the Therapy of T-Cell Acute Lymphoblastic Leukemia

Steffen Krohn, Carina Lynn Gehlert, Dorothee Winterberg, Alexander Jochimsen, Ammelie Svea Boje, Natalie Baum, Claudia D Baldus, Monika Brüggemann, Gunnar Cario, Martin Schrappe, Lennart Lenk, Martin Gramatzki, Katja Klausz, Christian Kellner, Matthias Peipp

Blood (2024) 144 (Supplement 1): 4173.

https://doi.org/10.1182/blood-2024-207737

Published: 2024

Journal Articles

Drug Sensitivity and Treatment Response Are Modulated By the Cell of Origin, the Underlying Gene Fusion, and Patient Age in KMT2A -Rearranged BCP-ALL

Blood (2024) 144 (Supplement 1): 318.

https://doi.org/10.1182/blood-2024-199017

Published: 2024

Journal Articles

CD127-Directed Immunotherapy with Lusvertikimab Outperforms Imatinib in Preclinical ABL-Class-Fusion-Positive BCP-ALL

Blood (2024) 144 (Supplement 1): 636.

https://doi.org/10.1182/blood-2024-205421

Published: 2024

Journal Articles

IDH2 Mutations from Clonal Hematopoiesis and Acquired IKZF1 Deletions Define a Novel B-ALL Subtype after Lenalidomide Therapy for Multiple Myeloma

Blood (2024) 144 (Supplement 1): 631.

https://doi.org/10.1182/blood-2024-199601

Published: 2024

Journal Articles

Outcome of Patients with Hematologic or Molecular Relapsed/Refractory (R/R) Acute T- Lymphoblastic Leukemia - Data from the GMALL Study Group

Anjali Cremer, Maher Hanoun, Ralph Wäsch, Simon Raffel, Klaus Wethmar, Andreas Viardot, Walter Fiedler, Knut Wendelin, Lore Marretta, Wolfram Jung, Roland Schroers, Vladan Vucinic, Monika Brüggemann, Stefan Schwartz, Hubert Serve, Nicola Goekbuget

Blood (2024) 144 (Supplement 1): 1436.

https://doi.org/10.1182/blood-2024-202270

Published: 2024

Journal Articles

A Novel 12-Color 2-Tube Next Generation Flow Approach Enables Sensitive Detection of Measurable Residual Disease in Virtually All T-Cell Acute Lymphoblastic Leukemia Patients

Lukasz Sedek, Beatriz Soriano, Łukasz Słota, Monika Brüggemann, Aleksandra Lasia, Saskia Kohlscheen, Michaela Reiterova, Stefan Nierkens, Anja De Jong, Giuseppe Gaipa, Cristina Bugarin, Cristiane Ferreira-Facio, Elaine Sobral da Costa, Ludovic Lhermitte, Julia Almeida, Alberto Orfao, Jacques JM van Dongen, Tomasz Szczepanski

Blood (2024) 144 (Supplement 1): 4218.

https://doi.org/10.1182/blood-2024-208387

Published: 2024

Journal Articles

Recurrent Molecular Variants, Clonal Evolution and Clinical Relevance in T-Cell Lymphoblastic Neoplasia Comparing Lymphoma and Leukemia Samples Derived from Children and Adults

Sarah Sandmann, Marcel Te Vrugt, Gerrit Randau, Thomas Beder, Martin Neumann, Amelie Alfert, Cornelia Eckert, Anja Moericke, Johanna Horns, Monika Brüggemann, Birgit Burkhardt

Blood (2024) 144 (Supplement 1): 2832.

https://doi.org/10.1182/blood-2024-205213

Published: 2024

Journal Articles

Integrateall, a Machine Learning Pipeline for Multi-Level Data Extraction from RNA-Seq Profiles Unravels Novel Drivers and Systematic Subtype Classification in B-Cell Precursor ALL

Nadine Wolgast, Thomas Beder, Mayukh Mondal, Wencke Walter, Stephan Hutter, Sonja Bendig, Jan Kässens, Björn-Thore Hansen, Katharina Iben, Barz Malwine, Martin Neumann, Nicola Goekbuget, Claudia Haferlach, Monika Brüggemann, Claudia D Baldus, Alina M. Hartmann, Lorenz Bastian

Blood (2024) 144 (Supplement 1): 4213.

https://doi.org/10.1182/blood-2024-199557

Published: 2024

Journal Articles

Data-Informed, Refined Immunophenotypic Classification of Adult T-Lineage Acute Lymphoblastic Leukemia

Stefan Habringer, Iva Todorova, Frederik Herzberg, Daniel Steiert, Arik Horne, Thomas Burmeister, Simon Haas, Ulrich Keller, Monika Brüggemann, Michaela Kotrova, Claudia D Baldus, Nicola Goekbuget, Martin Neumann, Stefan Schwartz

Blood (2024) 144 (Supplement 1): 1460.

https://doi.org/10.1182/blood-2024-202301

Published: 2024

Journal Articles

Circulating Tumor DNA Kinetics at Day 14 after CAR T-Cell Therapy Identifies Patients with B-Cell Lymphoma at Risk for Early Treatment Failure

Tim Versteegen, Philipp Nakov, Nikos Darzentas, Guranda Chitadze, Ingram Iaccarino, Wolfram Klapper, Natalie Schub, Monika Brüggemann, Friedrich Stoelzel, Claudia D Baldus, Christiane Pott, Mouhamad Khouja

Blood (2024) 144 (Supplement 1): 2959.

https://doi.org/10.1182/blood-2024-207721

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Liquid biopsy for non-invasive molecular characterization and measurable residual disease analysis in multiple myeloma

Impact of IKZFplus status and ABL1 kinase domain mutations in patients with newly diagnosed Philadelphia-chromosome positive acute lymphoblastic leukemia receiving imatinib and chemotherapy followed by allogeneic SCT within GMALL07/03

First promising results in younger adult patients (<65 yrs) with newly diagnosed ph/BCR::ABL positive ALL treated within the randomized GMALL evolve trial

IL-1β-induced signaling modulates cytokine release and apoptosis in IDH1-mutant AML

Late re-expansion and high-level persistence of CAR T-cells can be driven by single CAR+ T-cell clones without clinically evident CAR+ T-cell lymphoma

Outcome of adult B-precursor acute lymphoblastic leukemia (ALL) treated with blinatumomab in addition to chemotherapy independent of MRD: First results from the national GMALL registry

Efficacy of single-agent subcutaneous blinatumomab in adults with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL): Results from a phase 1/2 dose expansion study with extended follow-up

Baseline T-cell fitness and subtype-specific CD19 loss as drivers of blinatumomab resistance in B-ALL

NGS-based IG/TR gene rearrangement profiling in acute lymphoblastic leukemia: age dependence of immunogenetic maturation

MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trial

Preclinical Development of a Novel Humanized and Fc-Engineered Antibody-Drug Conjugate for the Therapy of T-Cell Acute Lymphoblastic Leukemia

Drug Sensitivity and Treatment Response Are Modulated By the Cell of Origin, the Underlying Gene Fusion, and Patient Age in KMT2A -Rearranged BCP-ALL

CD127-Directed Immunotherapy with Lusvertikimab Outperforms Imatinib in Preclinical ABL-Class-Fusion-Positive BCP-ALL

IDH2 Mutations from Clonal Hematopoiesis and Acquired IKZF1 Deletions Define a Novel B-ALL Subtype after Lenalidomide Therapy for Multiple Myeloma

Outcome of Patients with Hematologic or Molecular Relapsed/Refractory (R/R) Acute T- Lymphoblastic Leukemia - Data from the GMALL Study Group

A Novel 12-Color 2-Tube Next Generation Flow Approach Enables Sensitive Detection of Measurable Residual Disease in Virtually All T-Cell Acute Lymphoblastic Leukemia Patients

Recurrent Molecular Variants, Clonal Evolution and Clinical Relevance in T-Cell Lymphoblastic Neoplasia Comparing Lymphoma and Leukemia Samples Derived from Children and Adults

Integrateall, a Machine Learning Pipeline for Multi-Level Data Extraction from RNA-Seq Profiles Unravels Novel Drivers and Systematic Subtype Classification in B-Cell Precursor ALL

Data-Informed, Refined Immunophenotypic Classification of Adult T-Lineage Acute Lymphoblastic Leukemia

Circulating Tumor DNA Kinetics at Day 14 after CAR T-Cell Therapy Identifies Patients with B-Cell Lymphoma at Risk for Early Treatment Failure

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only